-- Creating new models of drug-resistant cancer: ATCC and the Broad Institute collaborated to develop CRISPR-engineered drug-resistant isogenic cell lines that replicate clinically observed resistance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results